The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XRTX | -49.75% | -93.37% | -41.63% | -96% |
| S&P | +14.77% | +87.2% | +13.35% | +153% |
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.
No news articles found for Xortx Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$29.39K | -13.2% |
| Market Cap | $4.22M | -11.4% |
| Market Cap / Employee | $248.22K | 0.0% |
| Employees | 17 | 0.0% |
| Net Income | -$649.47K | -10.6% |
| EBITDA | -$686.81K | 19.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.19M | -48.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $59.09K | -3.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -58.35% | -44.3% |
| Return On Invested Capital | -71.40% | -78.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$634.83K | 16.0% |
| Operating Free Cash Flow | -$634.83K | 16.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.54 | 1.00 | 1.25 | 1.51 | -14.21% |
| Price to Tangible Book Value | 1.68 | 1.06 | 1.34 | 1.67 | -11.02% |
| Enterprise Value to EBITDA | -2.04 | -1.90 | -2.79 | -4.04 | 43.96% |
| Return on Equity | -83.1% | -38.0% | -79.4% | -94.6% | 427.95% |
| Total Debt | $38.79K | $15.66K | $80.47K | $59.09K | -3.86% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
